Miami Heart Study - Subclinical Atherosclerosis and the Genetics of Cardiovascular Medicine

Course overview

Cardiovascular disease is the leading contributor to years lost due to disability or premature death among adults. Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, and accounts for a large share of total healthcare expenditure.  While CVD risk assessment in general has been traditionally guided by risk estimates derived from scores combining traditional risk factors, there is a growing body of evidence showing that such an approach lacks sufficient accuracy in predicting risk of future events among asymptomatic individuals. Substantial progress has been made in the discovery of genetic characterization contributing to the risk of coronary artery disease and the refinement of polygenic risk scores. Dr. Theodore Feldman, Dr. Khurram Nasir and Dr. Ricardo Cury discuss how the Miami Heart Study at Baptist Health South Florida aims to provide important, novel insights into the pathophysiology of early subclinical atherosclerosis and further the understanding of its role in the genesis of clinical CVD.  Dr. Pradeep Natarajan discusses the evidence supporting the use of both clinical and genetic risk scoring to predict incident coronary artery disease and indicate the clinical response to some preventive therapies.  Topics include: Lessons from the Miami Heart Study: Imaging Insights Miami Heart Study Update Miami Heart Study (MiHeart) at Baptist Health South Florida Applications of Genetics to Cardiovascular Medicine